Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
For adult nonvalvular AF, do not use edoxaban above CrCl 95 mL/min. Give 60 mg once daily at CrCl above 50 through 95, or 30 mg once daily at 15-50 mL/min. Use below 15 is not recommended.
Limits and monitoring
The upper clearance restriction applies to AF. DVT/PE has separate eligibility, initial parenteral therapy, weight and interacting-drug criteria.
Before use
Apply only to the stated formulation, indication and renal population.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Renal guidance: Boxed Warning, sections 2.1 and 8.6
Limits that apply to these rows
The upper clearance restriction applies to AF. DVT/PE has separate eligibility, initial parenteral therapy, weight and interacting-drug criteria.
Nonvalvular atrial fibrillation in adults
Cockcroft-Gault CrCl (mL/min)
Edoxaban oral regimen
>95
Do not use for NVAF
>50 to 95
60 mg once daily
15 to 50
30 mg once daily
<15
Not recommended
Read the retained text before reformatting
For adult nonvalvular AF, do not use edoxaban above CrCl 95 mL/min. Give 60 mg once daily at CrCl above 50 through 95, or 30 mg once daily at 15-50 mL/min. Use below 15 is not recommended. The upper clearance restriction applies to AF. DVT/PE has separate eligibility, initial parenteral therapy, weight and interacting-drug criteria.
Source revision: DailyMed SPL version 28, posted Jul 14, 2025 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Savaysa - product and source limitations
The upper clearance restriction applies to AF. DVT/PE has separate eligibility, initial parenteral therapy, weight and interacting-drug criteria.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Edoxaban tablets (Savaysa, adults) - selected U.S. label sections
Adult SAVAYSA oral tablets; atrial fibrillation and venous thromboembolism are distinct indications.
Method: Cockcroft-Gault creatinine clearance in mL/min
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
After 5-10 days of parenteral anticoagulation, the usual labeled dose is 60 mg once daily. Reduce to 30 mg once daily for CrCl 15-50 mL/min, body weight at or below 60 kg, or specified P-gp inhibitors. This summary does not provide an ESRD or dialysis regimen.
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
Renal guidance: Boxed Warning, sections 2.1 and 8.6
Limits that apply to these rows
The upper clearance restriction applies to AF. DVT/PE has separate eligibility, initial parenteral therapy, weight and interacting-drug criteria.
Nonvalvular atrial fibrillation in adults
Cockcroft-Gault CrCl (mL/min)
Edoxaban oral regimen
>95
Do not use for NVAF
>50 to 95
60 mg once daily
15 to 50
30 mg once daily
<15
Not recommended
Read the retained text before reformatting
For adult nonvalvular AF, do not use edoxaban above CrCl 95 mL/min. Give 60 mg once daily at CrCl above 50 through 95, or 30 mg once daily at 15-50 mL/min. Use below 15 is not recommended. The upper clearance restriction applies to AF. DVT/PE has separate eligibility, initial parenteral therapy, weight and interacting-drug criteria.
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
